Since the introduction of the laryngeal mask airway (LMA) in the early 1980s, a number of new supraglottic airway devices have been developed for the management of both normal and difficult airways under general anaesthesia 1 . As day surgery becomes more popular, supraglottic airways are being increasingly used.
Streamlined Liner of the Pharynx Airway (SLIPA™, SLIPA Medical Limited, UK) ( Figure 1 ) is a recently developed supraglottic airway, intended for use as a primary airway management device for short surgical procedures. SLIPA is a single-use, latex-free, non-cuffed supraglottic airway which is fabricated from soft plastic with the anatomically preformed shape of the pressurised pharynx 2 . It has been reported to be reliable and easy-to-use for both spontaneous and controlled ventilation during general anaesthesia 2, 3 . Furthermore, the device contains a hollow chamber to minimise the risk of aspiration during controlled ventilation 3, 4 .
Structural differences from the airway devices could influence the different compressive/stretching forces within the oral and pharyngeal cavities, and require different depth of anaesthesia. Different depth of anaesthesia should be considered depending on the airway devices to minimise fluctuating SUMMARY This study was designed to determine the optimal dose of remifentanil required for the successful insertion of Streamlined Liner of the Pharynx Airway (SLIPA™) and to compare it to that required for laryngeal mask airway (LMA) insertion in patients receiving a propofol infusion at a standard effect-site concentration.
Fifty-eight patients scheduled to undergo general anaesthesia were randomly assigned to either the SLIPA (n=29) or LMA (n=29) group. All patients were premedicated with midazolam 0.05 mg.kg -1 and glycopyrrolate 0.004 mg.kg -1 intramuscularly. After the administration of lignocaine 1 mg.kg -1 intravenously, a propofol infusion was started at an effect-site concentration of 3.5 µg.ml -1 with a remifentanil infusion without a neuromuscular blocking agent. The remifentanil dose was determined by the modified up-and-down method starting in each group at 4 ng.ml -1 . Six minutes after induction, the airway device was inserted. Airway device insertion was classified as 'success' or 'failure' based on patient response.
From the isotonic regression analysis and bootstrap distribution, the EC 50 of remifentanil for SLIPA and LMA were 0.93 ng.ml -1 (95% confidence interval [CI] 0.81 to 1.50 ng.ml -1 ) and 1.36 ng.ml -1 (95% CI 1.19 to 2.06 ng.ml -1 ) respectively, and the EC 95 for SLIPA and LMA insertions were 1.90 ng.ml -1 (95% CI 1.39 to 1.95) and 2.43 ng.ml -1 (95% CI 1.80 to 2.46 ng.ml -1 ) respectively. Using the 83% CIs from the bootstrap distribution, EC 50 for SLIPA was significantly less than that of LMA (0.83 to 1.23 vs 1.26 to 2.00, respectively) (P <0.05).
These findings suggest that the insertion of SLIPA needs about a 32% lower depth of anaesthesia than LMA insertion.
haemodynamic responses after airway insertion, especially in patients with a pre-existing myocardial or cerebrovascular insufficiency. The effectiveness of and haemodynamic responses to SLIPA insertion have also been compared with conventional LMA [3] [4] [5] , but little information is available regarding the optimal effect-site concentration of remifentanil required for the successful insertion of SLIPA during the target-controlled infusion (TCI) of propofol.
This study was designed to determine the optimal effect-site concentrations of remifentanil in 50% and 95% of adults (EC 50 and EC 95 ) for the successful insertion of SLIPA using the modified up-and-down method and to compare these to those required for LMA (SoftSeal™; Smith Medical International Ltd, Hythe, UK) insertion in patients receiving propofol infusion at an effect-site concentration of 3.5 µg.ml -1 without a neuromuscular blocking agent.
MATERIALS AND METHODS

Patients
After obtaining the approval of our institutional ethics committee and written informed consent, we enrolled 58 patients aged 18 to 60 years of American Society of Anesthesiologists physical status I or II scheduled to undergo elective minor surgery requiring general anaesthesia. Excluded from the study were patients with a potentially difficult airway (Mallampati grade III or IV, a mouth-opening of <25 mm, or cervical spine disease), signs of upper respiratory infection, history of reactive airway disease, gastro-oesophageal reflux, hepatic or renal disorders, a history of drug abuse or a long-term use of benzodiazepines or tricyclic antidepressants.
Modified up-and-down method
The first patient in each group received an effectsite remifentanil concentration of 4 ng.ml -1 , based on the estimate EC 50 required for LMA insertion from the previous study 6 . The effect-site concentration of remifentanil used in each patient was predetermined by response of the previously tested patient using the modified up-and-down method 7, 8 . If the airway device was inserted successfully, the target effectsite concentration of remifentanil was reduced by 1.0 ng.ml -1 for the next patient, and if insertion failed, the target effect-site concentration was increased by the same dose. According to the modified upand-down method 6, 8 , the first stage consisted of an up-and-down sequence (using a 1.0 ng.ml -1 step size) until three changes of response type were observed. After the first three such 'negative-positive' upand-down crossovers, the step size was reduced to 0.5 ng.ml -1 until a sample size of eight crossovers was reached in each group.
Anaesthesia
All patients were premedicated with midazolam 0.05 mg.kg -1 and glycopyrrolate 0.004 mg.kg -1 intramuscularly 30 minutes before anaesthesia induction. Upon arrival in the operating room, an 18-gauge venous cannula was inserted in the dorsum of a hand and 8 to 10 mg.kg -1 and lactated Ringer's solution was infused. Patients were randomly assigned into either a SLIPA or LMA group for airway management during general anaesthesia using a computer-randomised table. Standard physiological monitoring included electrocardiography, pulse-oximetry, non-invasive arterial blood pressure and end-tidal CO 2 concentration monitoring. Depth of anaesthesia was monitored using an Entropy ® module (GE Healthcare, Helsinki, Finland); the state and response entropies were computed and displayed continuously using an S/5 M-entropy Module (GE Healthcare, Helsinki, Finland).
All patients were pre-oxygenated using 100% oxygen with a normal tidal volume for three minutes. The infusion port for propofol and remifentanil was connected as close as possible to the intravenous catheter to minimise deadspace. Before administering propofol, 1 mg.kg -1 of intravenous lignocaine was administered to reduce pain at the venous access site. Anaesthesia was induced using propofol and remifentanil at the predetermined concentration at an effect-site concentration of 3.5 µg.ml -1 using the modified up-and-down method 7, 8 . The first patient in each group received an effect-site remifentanil concentration of 4 ng.ml -1 . For effect-site TCI of propofol and remifentanil, commercial TCI pumps (Orchestra ® Base Primea, Fresenius Vial, France) were used. Propofol and remifentanil were administered according to the pharmacokinetic models of Schnider 9 and Minto 10 respectively. When a patient was unable to respond to verbal stimulus, ventilation was assisted manually to maintain an end-tidal CO 2 concentration of 35 to 45 mmHg. Neuromuscular blocking drugs were not given. Six minutes following administration of propofol and remifentanil, SLIPA or LMA insertion was attempted by the anaesthetist (who was unaware of the targeted effect-site concentration of remifentanil).
Insertion of airway devices
The LMA was inserted after partial inflation with 10 ml of air, as previously described 11 . The tip and the posterior aspect of the LMA were coated with a water-soluble lubricant. After the LMA had been inserted into the correct position, cuff was inflated with air until effective ventilation had been established or the maximum recommended inflation volume had been reached. SLIPA insertion was facilitated by a jaw thrust (performed by an assistant) in all patients 4 . The toe and posterior aspect of the SLIPA were coated with the same lubricant. Airway devices were inserted in all cases by a single anaesthetist who had used LMA in at least 1000 cases and SLIPA in 50 cases. Appropriate airway device sizes were left to the attending anaesthetist's discretion. The sizes of SLIPA and LMA used ranged from 47 to 53 and from 3 to 4 respectively. LMA was sized according to the standard practice. Sizing of SLIPA was performed by matching the width of the thyroid cartilage with that of the bridge of the SLIPA 5 . Airway device insertion was classified as 'success' or 'failure' based on patient response. 'Failure' was defined as patient movement (coughing, straining, bucking, laryngospasm or gross purposeful movement) at first insertion attempt or within one minute of insertion. Also, significant resistance to mouth-opening (Muzi score 12 >2; 1=fully relaxed, 2=mild resistance, 3=resistance but could be opened, and 4=resistance requiring further propofol) was defined as 'failure'. Two independent observers performed the patient movement assessments. Muzi scores were determined by the anaesthetist who placed the airway device. If insertion failed, further doses of propofol or remifentanil were given according to the patient's condition, then insertion was re-attempted.
Haemodynamic data
Heart rate, mean arterial pressure (MAP) and entropy values were measured and recorded at baseline (just before induction), before insertion and one minute after insertion. Hypotension was defined as a MAP of <60 mmHg or a MAP decrease of >30% from baseline persisting for more than two consecutive checks, and treated with a bolus of intravenous ephedrine (4 to 6 mg). Bradycardia was defined as a heart rate of <40 beats.minute -1 or a decrease of >30% from the baseline, and was treated with 0.5 mg of intravenous atropine. The haemodynamic and entropy data of failed cases were excluded from the analysis.
Statistical analysis
The up-and-down process was repeated until the eighth cross-over point from 'failure' to 'success' was obtained. Besides the goal of estimating the target dose from the up-and-down study, it is also necessary to specify the precision of the target dose with a 95% confidence interval (CI). Drug effect increases with increasing dose, but biologic and experimental variability may produce unexpected ups and downs in the observed response rate as dose increases ( Figure 2B ). Thus, the adjusted response rates were calculated by the pooled-adjacent-violators algorithm (adjusted response rates) ( Figure 2 ). The isotonic estimator of target dose with isotonic regression provides a smaller bias, mean square error, greater precision (tighter CI), and requires no symmetry assumption 13 . The bootstrapping method allows the estimation of CIs of the target dose with any probability of effect, not just the 50th quantile (e.g. EC 50 or EC 95 ) 13 . The EC 50 and EC 95 of remifentanil and CIs were calculated from the isotonic regression estimators and 9999 bootstrap replications. Comparison of EC 50 of remifentanil for each devices used the method of overlapping CIs. If 83% CIs were nonoverlapping, the null hypothesis of equal EC 50 was rejected at an α of approximately 0.05 14 .
Heart rate, MAP and entropy value changes were compared by repeated measures analysis of variance. P values less than 0.05 were considered statistically significant. All statistical calculations were performed using the SPSS version 17.0 for Windows (SPSS Inc, IL, USA) and R version 2.11.0 (R foundation for Statistical Computing, Vienna, Austria). As this was an exploratory study, no power calculation was performed.
RESULTS
Fifty-eight patients were enrolled in this study and randomly assigned to the SLIPA or LMA group. Patient ages and anthropometric measurements were similar in the two groups (Table 1) . Individual dose-response data for airway device insertion as determined using the modified up-and-down method are presented in Figure 2 . Inter-group comparisons of haemodynamic and Entropy data were performed using successful cases in each group.
To provide better precision and narrow CIs for point estimates, the isotonic regression estimation and the pooled-adjacent-violators algorithm approach were used ( Figure 3 Using the 83% CIs from the bootstrap distribution, the difference between SLIPA and LMA was statistically significant (P <0.05) 14 .
The MAP and heart rate values of successful insertions are summarised in Table 2 . MAP decreased significantly after propofol and remifentanil infusion versus baseline, but these decrements were not statistically different. Notably, a significant increased in MAP was observed after SLIPA insertion (before insertion 69.0±8.8 mmHg and at one minute after insertion 77.6±11.0 mmHg; P=0.021), whereas no significant change was observed after LMA insertion.
No patient developed hypotension or bradycardia requiring treatment.
DISCUSSION
Using the modified up-and-down method, this study shows that the SLIPA requires a lower EC 50 of remifentanil for successful insertion than the LMA during induction with propofol TCI of 3.5 µg.ml -1 without a neuromuscular blocking agent in adults.
The EC 50 value of remifentanil for SLIPA insertion is 32% less than that for LMA. This significant difference in the requirement of remifentanil during TCI propofol infusion for the placement of the two airway devices suggests that the SLIPA stimulates the upper airway during insertion less than the LMA. This difference can be explained by the different insertion techniques and sealing mechanisms used. The SLIPA is inserted by sliding it over the tongue, similar to a laryngoscope blade, and then slipped into position between the oesophagus and the nasopharynx. In contrast, the posterior aspect of the LMA is pressed up against the hard palate and the posterior pharyngeal wall in order to facilitate its passage around the posterior pharyngeal wall. This pressure applied to the pharyngeal wall might cause considerable stimulation during insertion. On the other hand, the SLIPA is a supraglottic airway with anatomically preformed shape-lines the pharynx and does not require cuff inflation, whereas the LMA can only form an effective seal in the narrow supraglottic region when the cuff is inflated, which also might result in greater stimulation.
During the study, it was found that MAP had increased significantly at one minute after SLIPA insertion (P=0.021) but not after the LMA. However, these differences in MAP increase between the two devices were not significantly different (P=0.114). This finding is consistent with those of previous studies that compared haemodynamic responses to SLIPA with LMA insertion 4,5 . Puri et al 5 found that MAP rose significantly following the insertions of both devices and that MAP rose significantly more after SLIPA insertion than after conventional LMA insertion (P <0.05), whereas bispectral index responses for these two devices were similar. They concluded that the preformed shape of SLIPA might stimulate a greater cardiovascular response to insertion, and therefore suggested that SLIPA™ requires a slightly deeper plane of anaesthesia 4, 5 .
Nevertheless, in the present study, it was found that SLIPA required a lower EC 50 of remifentanil than the LMA for successful insertion. However, it is difficult to compare the haemodynamic responses of the two devices directly because different doses of remifentanil were administered to patients. Accordingly, we suggest that further study using a constant effect-site concentration is required to compare haemodynamic response following SLIPA and LMA insertion.
Several studies have been performed to determine the optimal effect-site concentration of propofol for successful LMA insertion using the TCI system. In the present study, we used remifentanil rather than fentanyl and alfentanil to evaluate anaesthetic requirements for successful airway insertion. Remifentanil is ultra-short-acting, has a rapid onset of action (blood-brain equilibration time of one minute), a high clearance rate, and a short elimination half-life (<10 minutes) 10 . In addition, remifentanil provides improved jaw relaxation 19 and reduces propofol requirements 20 . Furthermore, it facilitates LMA insertion with minimal adverse haemodynamic changes during propofol induction 6 . Given these properties, effect-site concentrations of remifentanil can be precisely controlled using TCI as compared with the intravenous bolus technique for successful airway insertion.
In the present study, the EC 50 of remifentanil for successful LMA insertion was 1.78 (0.62) ng.ml -1 , whereas Kim et al 6 reported that the EC 50 of remifentanil for conventional LMA was 3.04 (0.49) ng.ml -1 during induction using propofol TCI at 3.5 µg.ml -1 . This substantial difference in remifentanil requirements could be explained by study design differences. First, we gave midazolam as a sedative premedication and intravenous lignocaine to reduce pain before administering propofol. Midazolam reduces the dose of propofol required to induce anaesthesia and permits LMA insertion 16 . In addition, lignocaine may suppress laryngeal reflexes and cardiovascular responses during airway insertion 17 . Thus, remifentanil-midazolam-lignocaine combinations may synergistically facilitate insertion. Second, LMA SoftSeal used in this study might provide adequate ventilation at a lower sealing cuff volume and pressure rather than conventional LMA devices. SoftSeal differs from the conventional LMA with respect to cuff material, thickness, volume and compliance, and better fits the contours of the hypopharynx than a conventional LMA 21 .
A number of limitations exist regarding our study. First, the patients included in this study were all Korean. The data collected in this study cannot necessarily be extrapolated to the use in a Caucasian population. Careful consideration should be taken in choosing an effect-site concentration, because there might be variability between patients as well as interracial differences. Second, as this study does not provide power calculations, all outcomes including haemodynamic data are exploratory.
In conclusion, we found that SLIPA insertion needs about a 32% lower depth of anaesthesia than LMA insertion. Using the modified up-anddown method, the EC 50 of remifentanil required for SLIPA and LMA insertions during a propofol TCI at 3.5 µg.ml -1 without a neuromuscular blocking agent was 0.93 ng.ml -1 (95% CI 0.81 to 1.50 ng.ml -1 ) and 1.36 ng.ml -1 (95% CI 1.19 to 2.06 ng.ml -1 ), respectively.
